Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Allogene Therapeutics Terminates Asian CAR-T Joint Venture with Overland Pharmaceuticals – Strategic Retreat from Allogeneic Cell Therapy Market in Asia

Fineline Cube May 18, 2026
Company Deals

Eli Lilly Commits $50M to UNICEF USA Alliance Targeting Non-Communicable Disease Prevention in Children Across 21 LMICs

Fineline Cube May 15, 2026
Company Deals

TenNor Therapeutics Raises $71M in Hong Kong IPO – Antimicrobial Pipeline Targets H. pylori and Implant-Associated Infections

Fineline Cube May 14, 2026
Company Deals Drug

Fosun Pharma Secures Global Rights to AriBio’s Alzheimer’s Drug AR1001 in $240M Deal – PDE-5 Inhibitor Shows Promise in Phase III

Fineline Cube May 14, 2026
Company Deals

Merck & Co. Forges Four Strategic Partnerships with Chinese Biotechs to Advance Autoimmune and Oncology Pipeline Through MCICC Platform

Fineline Cube May 14, 2026
Policy / Regulatory

China Issues National Guidelines for Home Hospital Bed Services to Address Healthcare Access for Vulnerable Populations

Fineline Cube May 15, 2026
Company Drug

Harbour BioMed Unveils Preclinical Data for LET003 – AI-Discovered ACVR2A/2B Antibody Shows Best-in-Class Potential in Obesity Combination Therapy with GLP-1 Drugs

Fineline Cube May 18, 2026
Company Drug

AstraZeneca and Daiichi Sankyo’s ENHERTU Secures Dual FDA Approval for HER2-Positive Early Breast Cancer – Neoadjuvant and Adjuvant Indications Supported by Landmark Phase 3 Data

Fineline Cube May 18, 2026
Company Deals

Lepu Biopharma Licenses Potential Best-in-Class ADC MRG007 to ArriVent

Fineline Cube Jan 22, 2025

Lepu Biopharma Co., Ltd (HKG: 2157) has announced an exclusive licensing agreement with ArriVent BioPharma,...

Policy / Regulatory

Trump Signs Executive Order to Withdraw from WHO, Drawing Criticism

Fineline Cube Jan 21, 2025

President Donald Trump has signed an executive order indicating the withdrawal of the United States...

Hospital

Douyin Gains Approval to Establish Hospital in Beijing’s Zhongguancun

Fineline Cube Jan 21, 2025

The Beijing Municipal Health Commission has approved Douyin, the Chinese short-form video hosting service owned...

Company Medical Device

NMPA Approves Synaptic Medical’s Cryoablation Device and Gene Methylation Detection Kit

Fineline Cube Jan 21, 2025

China’s National Medical Products Administration (NMPA) has granted marketing approval for two new medical devices:...

Company Drug

Huadong Medicine’s MediBeacon TGFR System Receives FDA Marketing Clearance

Fineline Cube Jan 21, 2025

China-based Huadong Medicine Co., Ltd (SHE: 000963) has announced receiving marketing clearance from the US...

Company Drug

MediLink’s YL201 Receives Breakthrough Therapy Designation for Nasopharyngeal Carcinoma

Fineline Cube Jan 21, 2025

Suzhou-based biotech MediLink Therapeutics (Suzhou) Co., Ltd has announced receiving another breakthrough therapy designation (BTD)...

Company Drug

Jiangsu Lianhuan Completes Enrollment for Phase III Study of LH-1801 in Type 2 Diabetes

Fineline Cube Jan 21, 2025

China-based Jiangsu Lianhuan Pharmaceutical Co., Ltd (SHA: 600513) has announced the completion of subject enrollment...

Company Drug

Arrowhead’s Plozasiran Accepted for FDA Review in Familial Chylomicronemia Syndrome

Fineline Cube Jan 21, 2025

US-based Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) has announced that the New Drug Application (NDA) for...

Company Deals

Keymed and InnoCare Announce Licensing Deal for CD20xCD3 Bispecific Antibody with Prolium

Fineline Cube Jan 21, 2025

China-based Keymed Biosciences Inc. (HKG: 2162) and InnoCare Pharma (HKG: 9969, SHA: 688428) have jointly...

Company Drug

GSK’s Jemperli Approved for First-Line Endometrial Cancer Treatment in EU

Fineline Cube Jan 21, 2025

UK-based GSK plc (NYSE: GSK, LON: GSK) has announced receiving approval from the European Commission...

Company Drug

Kelun-Biotech’s Tagitanlimab Receives NMPA Clearance for Nasopharyngeal Carcinoma

Fineline Cube Jan 21, 2025

China-based Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd (HKG: 6990) has announced receiving another clearance from the...

Company Deals

Junshi Biosciences Licenses Toripalimab to LEO Pharma for EU and UK Markets

Fineline Cube Jan 21, 2025

China-based Shanghai Junshi Biosciences Co., Ltd (HKG: 1877, SHA: 688180) has announced a licensing agreement...

Company Drug

CARsgen Therapeutics Initiates Trial for Universal CAR-T Therapy KJ-C2320 in AML

Fineline Cube Jan 21, 2025

China-based CARsgen Therapeutics Holdings Ltd (HKG: 2171) has announced the first subject dosing in an...

Company Deals

Danaher Partners with Huashan Hospital to Develop Alzheimer’s Diagnostic Solutions

Fineline Cube Jan 21, 2025

US-based science and tech services giant Danaher Corporation (NYSE: DHR) has announced a partnership between...

Company Drug

Chongqing Genrix’s Xeligekimab Approved for Ankylosing Spondylitis by NMPA

Fineline Cube Jan 21, 2025

China-based Chongqing Genrix Bio Pharmaceutical Co., Ltd (SHA: 688443) has announced receiving approval from the...

Company Deals

Takeda to Establish China Innovation Center in Chengdu, Focusing on Digital Health

Fineline Cube Jan 21, 2025

Japan-headquartered Takeda (NYSE: TAK, TYO: 4502) has announced plans to establish the Takeda China Innovation...

Policy / Regulatory

NHSA Outlines 2025 Work Plan and 2024 Medical Insurance Status

Fineline Cube Jan 20, 2025

The National Healthcare Security Administration (NHSA) last week held a press conference, addressing questions regarding...

Company Drug

FDA Approves AstraZeneca’s Calquence for Mantle Cell Lymphoma

Fineline Cube Jan 20, 2025

UK-based pharmaceutical major AstraZeneca (AZ, NASDAQ: AZN) last week revealed that the US Food and...

Company Deals Medical Device

NAMSA to Acquire WuXi AppTec’s US Medical Device Testing Business

Fineline Cube Jan 20, 2025

US-based medical device contract research organization (CRO) NAMSA is set to acquire the medical device...

Company Drug

MHRA Approves Gilead’s Livdelzi for Primary Biliary Cholangitis

Fineline Cube Jan 20, 2025

The Medicines and Healthcare products Regulatory Agency (MHRA) last week signed off on US-based Gilead...

Posts pagination

1 … 224 225 226 … 667

Recent updates

  • Harbour BioMed Unveils Preclinical Data for LET003 – AI-Discovered ACVR2A/2B Antibody Shows Best-in-Class Potential in Obesity Combination Therapy with GLP-1 Drugs
  • Allogene Therapeutics Terminates Asian CAR-T Joint Venture with Overland Pharmaceuticals – Strategic Retreat from Allogeneic Cell Therapy Market in Asia
  • AstraZeneca and Daiichi Sankyo’s ENHERTU Secures Dual FDA Approval for HER2-Positive Early Breast Cancer – Neoadjuvant and Adjuvant Indications Supported by Landmark Phase 3 Data
  • Roche’s Tecentriq Secures FDA Approval for ctDNA-Guided Adjuvant Treatment in Muscle-Invasive Bladder Cancer – First MRD-Directed Immunotherapy with 41% Mortality Reduction
  • Biogen’s Zorevunersen Receives China Breakthrough Therapy Designation for Dravet Syndrome – First ASO Targeting SCN1A Gene in Rare Epileptic Encephalopathy
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Harbour BioMed Unveils Preclinical Data for LET003 – AI-Discovered ACVR2A/2B Antibody Shows Best-in-Class Potential in Obesity Combination Therapy with GLP-1 Drugs

Company Deals

Allogene Therapeutics Terminates Asian CAR-T Joint Venture with Overland Pharmaceuticals – Strategic Retreat from Allogeneic Cell Therapy Market in Asia

Company Drug

AstraZeneca and Daiichi Sankyo’s ENHERTU Secures Dual FDA Approval for HER2-Positive Early Breast Cancer – Neoadjuvant and Adjuvant Indications Supported by Landmark Phase 3 Data

Company Drug

Roche’s Tecentriq Secures FDA Approval for ctDNA-Guided Adjuvant Treatment in Muscle-Invasive Bladder Cancer – First MRD-Directed Immunotherapy with 41% Mortality Reduction

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.